

Press release from Emotra AB (publ)
Göteborg, February 3, 2014

Overwhelming interest in Emotra's rights issue

The closing date for registering interest in Emotra AB's (publ) rights issue was January 30, 2014. The total amount for this rights issue, in which the general public was also invited to participate, was approximately 9.7 MSEK. By the end date, Emotra had received applications totalling approximately 24.3 MSEK, or 250% of the intended issue amount. Consequently, 648,945 new shares will be issued and Emotra will receive a cash injection of approximately 9.7 MSEK before issue expenses.

"We are very pleased with the enormous interest shown in Emotra and our business. I would like to express my warm thanks to everyone who participated in this new share issue. This new capital will allow us to continue with our work, and finance the groundwork for the international launch of our EDOR method," says Claes Holmberg, Emotra's CEO.

Registration for and allocation of new shares

In total, we received applications amounting to 24,348,210 SEK. 638,501 shares (approximately 98.4 percent of the new issue volume) were allocated through right of priority. Those who have been allocated shares without right of priority will receive account statements. We expect to send these on February 3, 2014. Those who have registered for the share issue but were not allocated any shares will not be receiving an account statement.

Number of shares and share capital

Once the rights issue has been registered with the Swedish Companies Registration Office, Emotra's share capital will amount to SEK 938,670.30, divided into 2,595,780 shares.

Trading in BTA

Trading in fully paid-up registered shares (BTA) will be carried out on AktieTorget until the Swedish Companies Registration Office has registered this new issue. We expect this registration to be completed by the end of February 2014.

Financial Advisor

Emotra's Financial Advisor in connection with this new share issue was Sedermera Fondkommission.

For further information, please contact:

*Sedermera Fondkommission AB
Issuing services
Telephone: +46 431 47 17 00
E-mail: nyemission@sedermera.se*

*Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se*

*Lars-Håkan Thorell, Head of Research
Telephone: +46 733 95 31 20
E-mail: lars@emotra.se*

Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.